A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety andImmunogenicity of a Trivalent, Surface Antigen Inactivated Subunit InfluenzaVirus Vaccine Produced in Mammalian Cell Culture (Optaflu®) in Healthy Adults - Optaflu

ovartis Vaccines and Diagnostics GmbH0 个研究点开始时间: 2013年3月19日最近更新: 2013年11月11日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•In order to participate in this study, a subject must meet ALL of the
•following inclusion
•? Is a male or female volunteer ages 18 years or older, mentally competent, willing and able to give written informed consent prior to study entry;
•? Is able to comply with all the study requirements; and
•? Is in good health as determined by the outcome of medical history, physical examination, and clinical judgment of the investigator
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 63
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 63

排除标准

•In order to participate in this study, a subject must not meet any of the following exclusion criteria:
•? Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study;
•? Has a serious chronic or acute disease (in the judgment of the investigator) including, but not limited to
•- medically significant cancer (except for benign or localized skin cancer, cancer in remission for =10 years, or localized prostate cancer that has been clinically stable for >2 years without treatment)
•- medically significant advanced congestive heart failure (ie, New York Heart Association [NYHA] class III and IV)
•- chronic obstructive pulmonary disease (ie, Global initiative for chronic Obstructive Lung Disease [GOLD] stage III and IV)
•- autoimmune disease (including rheumatoid arthritis and excepting Hashimoto's thyroiditis that has been clinically stable for =5 years)
•- diabetes mellitus type I
•- poorly controlled diabetes mellitus type II
•- advanced arteriosclerotic disease
•- history of underlying medical condition such as major congenital abnormalities requiring surgery, chronic treatment, or associated with developmental delay (eg, Down's syndrome)
•- acute or progressive hepatic disease
•- acute or progressive renal disease
•- severe neurological (especially Guillain–Barré syndrome) or psychiatric disorder
•- severe asthma
•? Has a history of any anaphylactic reaction and/or serious allergic reaction to any component of the study vaccine (see section 5.1);
•? Has a known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:
•- receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study,
•- receipt of immunostimulants within the past 6 months,
•- receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within the past 3 months and for the full length of the study, or
•- suspected or known human immunodeficiency virus (HIV) infection or HIV related disease
•? Has known or suspected drug or alcohol abuse within the past 2 years;
•? Has bleeding diathesis or conditions associated with prolonged bleeding time that, in the investigator's opinion, would interfere with the safety of the subject;
•? Is not able to comprehend and to follow all required study procedures for the whole period of the study;
•? Has a history or any illness that, in the opinion of the investigator, would pose additional risk to the subjects because of participation in the study;
•? Has the following within the past 6 months:
•- had any laboratory confirmed seasonal or pandemic influenza disease
•- received any seasonal or pandemic influenza vaccine
•? Has received any other vaccine within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine during the study;
•? Has acute or chronic infections requiring antiviral therapy within the last 7 days;
•? Has experienced fever (ie, body temperature [preferably oral] =38.0°C) within the last 3 days of intended study vaccination;
•? Has been participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intends to participate in another clinical study at any time during the conduct of t

研究者

发起方

ovartis Vaccines and Diagnostics GmbH

相似试验

进行中（未招募）

不适用

Seasonal Fluvirin trial 2013/14Prophylaxis of influenzaMedDRA version: 15.1Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestations

EUCTR2013-000601-23-DEovartis Vaccines and Diagnostics S.r.l.

进行中（未招募）

1 期

A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.Diffuse large B-cell lymphoma (DLBCL)MedDRA version: 21.0Level: LLTClassification code 10012883Term: Diffuse lymphomaSystem Organ Class: 100000004864

EUCTR2021-006049-36-NOIncyte Corporation81

进行中（未招募）

1 期

A Phase 3 study of Tafasitamab plus Lenalidomide in patients withRelapsed or Refractory Diffuse Large B-Cell Lymphoma.

EUCTR2021-006049-36-DKIncyte Corporation81

进行中（未招募）

1 期

EUCTR2021-006049-36-FIIncyte Corporation81

进行中（未招募）

1 期

EUCTR2021-006049-36-CZIncyte Corporation81